Abstract
The boron drug Na2B12H11SH (BSH) is presently being used in a clinical Phase I trial for glioma treatment with boron neutron capture therapy (BNCT). This study is carried out in The Netherlands at the High Flux Reactor of the European Commission. Patients are recruited from six neurosurgical centers in five European countries.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gabel, D., Touw, D., Stecher-Rasmussen, F., Huiskamp, R., Sauerwein, W. (2001). Quality Control for Na2B12H11SH, a Drug for Boron Neutron Capture Therapy in EORTC Trial 11961. In: Hawthorne, M.F., Shelly, K., Wiersema, R.J. (eds) Frontiers in Neutron Capture Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1285-1_34
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1285-1_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5478-9
Online ISBN: 978-1-4615-1285-1
eBook Packages: Springer Book Archive